U.S. Appl. No.: 10/725,276

Attorney Docket No.: 67824.428922

(Formerly T1530-00119)

Response Dated December 18, 2007

In Response to the Office Action of April 18, 2007

REMARKS

This Reply is believed to be fully responsive to the final Office Action mailed on October 17, 2007. By the present amendments claims 287-337 are retained and new claims 338 and 339 and 340 added which provide for the T1R2 polypeptide to be expressed by different taste or gastrointestinal cells. These claims find support in the original application for example at paragraphs 27, 64-67 et seq..

The new claims and the terminal disclaimers provided herewith should place this case in condition for allowance.

Turning now to the Office Action all the previous pending claims were rejected based on double patenting grounds. Particularly, claims 287-337 stand rejected based on claims 1-76 of commonly assigned, US Patent No. 6,955,887 and stand provisionally rejected over claims 272-306 of US Serial No. 10/725,284.

In order to expedite grant Applicants submit herewith Terminal Disclaimers terminally disclaiming the '887 patent and the above-identified co-pending commonly assigned patent application.

Withdrawal of the double patenting rejection of the claims is therefore respectfully requested.

As these were the only rejections, this reply and Terminal Disclaimers should place this case in condition for allowance.

Based on the foregoing, a Notice to that effect is respectfully solicited. Reconsideration and allowance of all claims are respectfully requested. However, if any issues remain after consideration of this Amendment, Examiner Brannock is respectfully requested to contact the undersigned by

9

U.S. Appl. No.: 10/725,276

Attorney Docket No.: 67824.428922

(Formerly T1530-00119)

Response Dated December 18, 2007

In Response to the Office Action of April 18, 2007

telephone (703-714-7645) so that these issues can be resolved by Examiner's Amendment or a Supplemental Response.

Applicants believe that no fee is due with the filing of this Amendment. However, in the event that the calculations of the Office differ, Commissioner is hereby authorized to charge or credit any such variance or credit any overpayment to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: December 18, 2007

Robin L. Teskin Reg. No. 35,030

Hunton & Williams LLP 1900 K Street, N.W. Suite 1200

Washington, D.C. 20006-1109 Phone: (202) 955-1500

Phone: (202) 955-1500 Fax: (202) 778-2201